maintaining peritoneal dialysis
Conditions
Interventions
1:1.0mmol/L initial treatment
2:1.0mmol/L treated
3:1.25mmol/L initial treatment
4:1.25mmol/L treated
5:1.75mmol/L initial treatment
6:1.75mmol/L treated
Sponsors
Rui'an People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with chronic renal failure (in line with clinical diagnostic guidelines); 2. Malnutrition assessment: at least 2 of the following 3 criteria are met: (1) serum pre-albumin less than or equal to 300mg/L or albumin less than or equal to 3.5g/dL; (2) the protein intake estimated by the standard protein total nitrogen exposure rate (nPNA) is no more than 0.9g/kg of ideal body weight; (3) subjective comprehensive evaluation (SGA) is more than 8 points; 3. Patients aged 18-75 years old, male or female, are not limited; 4. Sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Allergic to any amino acid or adjuvant in this product; 2. Patients with known glycogen storage disorder and uncontrolled diabetes mellitus (fasting blood glucose >200mg/dl, HbA1c >7.2%); 3. Serum urea is higher than 38mmol/L, with symptoms of uremia, metabolic acidosis, electrolyte disorder, congenital amino acid metabolism defects, acute severe pancreatitis, severe hyperbilirubinemia, hyperuricemia; 4. Hyperthyroidism, systemic infection, fever and other diseases of high catabolic state, as well as taking drugs affecting tissue metabolism, such as corticokin-like drugs; 5. Patients with malignant tumor metastasis or diffusion, residual cancer focus after treatment, coagulation dysfunction, aplastic anemia, heart, brain, lung and other serious diseases of the system; 6. Hepatitis b or hepatitis c active stage, cirrhosis, active liver disease, liver insufficiency or positive serum response to human immunodeficiency virus (HIV); 7. Acute or chronic catheter outlet infection, or tunnel infection; There are serious diseases affecting the abdominal wall (such as skin infection or burns, recent surgery, hernia) or the abdominal cavity (such as intestinal obstruction, adhesion, intestinal perforation, diaphragmatic defect, tumor); 8. Peritonitis occurred more than once within 6 months before the test, or did not fully recover from the previous peritonitis when participating in the test; 9. Kidney transplantation may be accepted during the study period; 10. Less than 6 months survival expectancy; 11. Participated in clinical trials of other drugs within 3 months before enrollment; 12. Pregnant and nursing women; 13. Mental state is not a good collaborator; 14. The clinician did not consider this study appropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| peritoneal mesothelial cell; | — |
Secondary
| Measure | Time frame |
|---|---|
| hemoglobin;hs-CRP;ALB;CHO;TG;Ca;P;PTH; | — |
Countries
China
Contacts
Public ContactChusheng Miao
Rui'an People's Hospital
Outcome results
None listed